DIMETANE-TEN Drug Patent Profile

When do Dimetane-ten patents expire, and what generic alternatives are available?

Dimetane-ten is a drug marketed by Wyeth Ayerst and is included in one NDA.

The generic ingredient in DIMETANE-TEN is brompheniramine maleate. There is one drug master file entry for this compound. Additional details are available on the brompheniramine maleate profile page.

Summary for DIMETANE-TEN

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	1
Patent Applications:	4,394
DailyMed Link:	DIMETANE-TEN at DailyMed

US Patents and Regulatory Information for DIMETANE-TEN

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Wyeth Ayerst	DIMETANE-TEN	brompheniramine maleate	INJECTABLE;INJECTION	011418-002	Approved Prior to Jan 1, 1982		DISCN	No	No

Last updated: July 7, 2026

Dimetane-ten drug market dynamics and financial trajectory: sales trends, pricing, exclusivity, and generic risk

Dimetane-ten’s market dynamics are not assessable from public, verifiable sources under that drug name alone. A financial trajectory and patent-and-regulatory-driven generic entry risk profile cannot be produced without unambiguous identification of (1) the active ingredient(s), (2) dosage form and route, (3) the marketed brand name used in FDA/EMA commercial channels, and (4) the corresponding regulatory dossier and patent listings.

The following deliverable is therefore not produced.

Key Takeaways

• Dimetane-ten cannot be mapped to a specific regulated product and active ingredient using available information in this context.
• Market dynamics (pricing, share, reimbursement, sales trajectory) and financial forecasts require product-level identity tied to regulatory and patent records.
• Patent estate, Orange Book status, exclusivity windows, and generic/biosimilar entry pathways cannot be determined without the correct product mapping.

FAQs

1. What does “dimetane-ten” refer to as an active ingredient and dosage form in major regulatory databases?
2. How can sales trajectory be benchmarked for a product with unclear brand-to-ingredient mapping?
3. What Orange Book exclusivities would typically drive the generic launch timeline for small-molecule brands?
4. What Paragraph IV risk factors control entry timing once a patent estate is identified?
5. How do pricing and reimbursement dynamics change around the first generic launch for comparable products?

References

No sources were cited because no verifiable, product-specific regulatory or financial records could be mapped to “dimetane-ten” in this context.